In this chapter the treatment of drug sensitive and drug resistant TB and timing of antiretroviral treatment for HIV infected patients will be reviewed. Emphasis is placed on results of recent trials of fluoroquinolones for treatment shortening of drug sensitive TB. The use of two relatively novel agents in MDR-TB treatment, bedaquiline and delamanid, will be discussed.
CITATION STYLE
Heemskerk, D., Caws, M., Marais, B., & Farrar, J. (2015). Treatment. In SpringerBriefs in Public Health (Vol. 2, pp. 39–49). Springer International Publishing. https://doi.org/10.1007/978-3-319-19132-4_5
Mendeley helps you to discover research relevant for your work.